

Expression of Interest (EOI)

Expression of Interest is invited to transfer the following technologies:

1) A recombinant protein-based ELISA and Lateral Flow Assay (LFA) for detection of brucellosis in animals and humans.

Description:

The assays are based on an immunogenic protein from *Brucella*, which has been expressed in *E. coli* and purified. The ELISA and LFA can efficiently differentiate *Brucella abortus* S19-vaccinated from naturally infected cattle (DIVA capability). The assays could be used for detection of anti-Brucella antibodies in animals and humans with high sensitivity and specificity. The assay technologies are available for transfer either individually or combined.

2) A peptide-based ELISA for detection of brucellosis in animals and humans.

The assay is based on an immunogenic peptide of 14 amino acids, which is derived from an immunogenic protein of *Brucella*. The ELISA can efficiently differentiate *Brucella abortus* S19-vaccinated from naturally infected cattle (DIVA capability). The assay could be used for detection of anti-Brucella antibodies in animals and humans with high sensitivity and specificity.

Interested firms/parties/companies may send their interest along with the brief profile of the Company/Industry addressed to Senior Manager, NIAB (<u>admin@niab.org.in</u>) with a copy to <u>girish@niab.org.in</u>

The last date for submission of Expression of Interest is 31 July 2020 by 5 PM.